<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594126</url>
  </required_header>
  <id_info>
    <org_study_id>CP14A004</org_study_id>
    <nct_id>NCT00594126</nct_id>
  </id_info>
  <brief_title>Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Refractory or Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geron Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geron Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of
      GRN163L when administered to patients with refractory or relapsed multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety
      of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and
      is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in
      antineoplastic effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and MTD</measure>
    <time_frame>First 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK, PD, and efficacy</measure>
    <time_frame>Baseline to end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3+3 cohort dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imetelstat Sodium (GRN163L)</intervention_name>
    <description>25% dose escalation infused over 2 hours weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of multiple myeloma (either secretory or nonsecretory disease)

          -  Relapsed or refractory disease

          -  At least two prior treatment regimens

          -  ECOG performance status 0-2

          -  Adequate hepatic/renal function and platelet count

          -  If previously treated with an anthracycline, anthracenedione, or trastuzumab, must
             have left ventricular ejection fraction &gt; 50%

        Exclusion Criteria:

          -  Prior allogeneic bone marrow transplant, including syngeneic transplant

          -  Known intracranial disease or epidural disease

          -  Prior malignancy (within the last 3 years)

          -  Clinically significant cardiovascular disease or condition

          -  Active or chronically recurrent bleeding (eg, active peptic ulcer disease

          -  Prolongation of PT or aPTT &gt; the ULN or fibrinogen &lt; the LLN

          -  Clinically relevant active infection

          -  Serious co-morbid medical conditions, including cirrhosis and chronic obstructive or
             chronic restrictive pulmonary disease

          -  Symptomatic hyperviscosity syndrome

          -  Any other cancer therapy within 3 weeks prior to study, except for mitomycin C,
             nitrosoureas, or high-dose chemotherapy with stem cell support within 6 weeks prior to
             study

          -  Investigational therapy within 4 weeks prior to study

          -  Anti-platelet therapy within 2 weeks prior to study, other than low dose aspirin
             prophylaxis therapy and low dose heparin administration for management of IV access
             devices

          -  Radiation therapy within 4 weeks prior to study

          -  Major surgery within 4 weeks prior to study

          -  Active autoimmune disease requiring immunosuppressive therapy

          -  Known positive serology for HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Kelsey, MD</last_name>
    <role>Study Director</role>
    <affiliation>Geron Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.geron.com</url>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Refractory Multiple Myeloma</keyword>
  <keyword>Relapsed or Refractory Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

